Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Sage ...
The global postpartum depression management market is set to grow steadily over the next decade, with a projected compound ...
On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 ...
Park Avenue Securities LLC cut its holdings in shares of Balchem Co. (NASDAQ:BCPC – Free Report) by 4.2% in the 3rd quarter, ...
Sage Therapeutics (NASDAQ:SAGE – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Raymond James in a note issued to investors on Thursday, MarketBeat.com reports.
John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...
Appili Therapeutics Inc. (the "Company" or "Appili"), announces correction to its press release entitled "Appili Therapeutics Announces Mailing of the Management Information Circular in Connection ...
On Wednesday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.49 which represents a slight increase of $0.06 or 0.93% from the prior close of $6.43. The stock opened at $6 ...
The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...
Former Columbia University psychiatrist Bret Rutherford, MD, committed research misconduct by "falsely reporting that all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback